Certara (NASDAQ:CERT) Price Target Cut to $16.00 by Analysts at Barclays

Certara (NASDAQ:CERT) had its target price trimmed by Barclays from $18.00 to $16.00 in a report released on Friday morning, Benzinga reports. The brokerage currently has an equal weight rating on the stock.

Several other brokerages have also weighed in on CERT. JMP Securities initiated coverage on shares of Certara in a report on Thursday, April 4th. They issued a market perform rating on the stock. Jefferies Financial Group lifted their price objective on Certara from $14.00 to $15.50 and gave the stock a hold rating in a research note on Friday, March 1st. UBS Group increased their target price on Certara from $17.00 to $20.00 and gave the company a neutral rating in a research note on Friday, March 1st. Finally, KeyCorp upgraded Certara from a sector weight rating to an overweight rating and set a $23.00 target price for the company in a research report on Wednesday, April 10th. Seven equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of Hold and a consensus target price of $19.81.

Certara Stock Up 1.5 %

NASDAQ CERT opened at $13.85 on Friday. The stock has a market capitalization of $2.23 billion, a P/E ratio of -35.51, a price-to-earnings-growth ratio of 4.68 and a beta of 1.58. Certara has a 52 week low of $11.81 and a 52 week high of $19.87. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.26 and a current ratio of 3.26. The stock has a fifty day moving average of $16.03 and a 200-day moving average of $16.87.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). Certara had a positive return on equity of 4.08% and a negative net margin of 17.02%. The firm had revenue of $96.65 million during the quarter, compared to analyst estimates of $94.48 million. On average, equities research analysts forecast that Certara will post 0.29 EPS for the current year.

Insider Activity

In related news, SVP Richard M. Traynor sold 3,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $18.00, for a total transaction of $54,000.00. Following the completion of the sale, the senior vice president now directly owns 173,524 shares of the company’s stock, valued at approximately $3,123,432. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, insider Patrick F. Smith sold 14,427 shares of the company’s stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $16.85, for a total transaction of $243,094.95. Following the completion of the transaction, the insider now directly owns 50,091 shares of the company’s stock, valued at $844,033.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Richard M. Traynor sold 3,000 shares of Certara stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $18.00, for a total value of $54,000.00. Following the completion of the sale, the senior vice president now directly owns 173,524 shares in the company, valued at approximately $3,123,432. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Certara

Hedge funds have recently made changes to their positions in the business. Pineridge Advisors LLC bought a new position in Certara in the fourth quarter valued at $28,000. Global Retirement Partners LLC boosted its stake in shares of Certara by 5,306.3% during the 1st quarter. Global Retirement Partners LLC now owns 1,730 shares of the company’s stock worth $31,000 after buying an additional 1,698 shares during the last quarter. YHB Investment Advisors Inc. bought a new position in shares of Certara in the 1st quarter valued at about $47,000. Natixis Advisors L.P. increased its position in shares of Certara by 13.4% in the third quarter. Natixis Advisors L.P. now owns 15,136 shares of the company’s stock valued at $220,000 after acquiring an additional 1,791 shares during the last quarter. Finally, Pacer Advisors Inc. raised its holdings in Certara by 1,704.0% during the fourth quarter. Pacer Advisors Inc. now owns 12,754 shares of the company’s stock worth $224,000 after acquiring an additional 12,047 shares in the last quarter. 73.96% of the stock is owned by institutional investors.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.